Janux Therapeutics (NASDAQ:JANX) Posts Earnings Results, Beats Estimates By $0.13 EPS

Janux Therapeutics (NASDAQ:JANX) released its earnings results on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.13, FiscalAI reports. The business had revenue of $9.29 million for the quarter, compared to analysts’ expectations of $8.03 million.

Janux Therapeutics Stock Performance

NASDAQ:JANX traded down $2.12 during trading hours on Thursday, reaching $16.06. The stock had a trading volume of 893,121 shares, compared to its average volume of 755,955. The stock has a market capitalization of $981.91 million, a PE ratio of -9.79 and a beta of 2.44. Janux Therapeutics has a 52 week low of $12.12 and a 52 week high of $35.34. The company has a 50 day moving average price of $17.52 and a two-hundred day moving average price of $15.39.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on JANX. TD Cowen raised Janux Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a report on Friday, October 16th. HC Wainwright reiterated a “buy” rating on shares of Janux Therapeutics in a research report on Monday, October 19th. Stifel Nicolaus set a $35.00 target price on shares of Janux Therapeutics in a report on Friday, August 7th. Finally, Wolfe Research upgraded shares of Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 target price for the company in a research report on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $36.46.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.